clinical trial · NCT04575467
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Caliway Biopharmaceuticals Co., Ltd.·phase2·completed·n = 25
Subcutaneous FatCBL-514
brief summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.
started
Dec 9, 2020
primary completion
Nov 15, 2021
completion
Dec 8, 2021
last updated
Aug 9, 2024
official title
A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol